Immunotherapy for ctDNA-positive colorectal cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal cancer that is not the MSI-H type.
- You had surgery to remove all visible cancer, followed by chemotherapy (like FOLFOX or CAPEOX).
- After chemotherapy, a blood test showed you still have small amounts of cancer DNA (ctDNA positive).
- You are generally healthy enough to be up and about (performance status ECOG 0 or 1).
- You have not had immunotherapy with drugs like PD-1 or CTLA-4 inhibitors before.
- You are willing to use effective birth control during and for 5 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests two new immunotherapy drugs (botensilimab and balstilimab) given after standard treatment for stage II or III colorectal cancer. The drugs are designed to boost your immune system to prevent cancer from coming back, especially if cancer cells are detected in your blood.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.